Our start-up portfolio

We've built an incredible production line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit. Our start-up portfolio secures funding from investors around the world who believe in our world class science and the power of partnership.

Three people in discussion sat at a table

79

start-ups formed across therapeutics, diagnostics and medtech

23

start-up exits to date

£3bn

raised by our start-up portfolio

Infinitopes £12.8m Seed financing

Featured start-up

“This fundraise enables us to pursue our uniquely integrated strategy of selecting the right targets, with the right vectors, for the right patients, at the right time in their treatment journey.”

-Jonathan Kwok, CEO and Co-founder of Infinitopes

Infinitopes is leading the cancer vaccine revolution. Cancer Research Horizons invested in its oversubscribed Seed funding round alongside Octopus Ventures, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors, to support the progression of its lead asset into the clinic.

52North

Seed | Medtech

Achilles Therapeutics

Therapeutics

ADC Therapeutics

Therapeutics

Adendra Therapeutics

Seed | Therapeutics

Akamis Bio

Therapeutics

Alethiomics

Therapeutics

Amplia Therapeutics

Therapeutics

Artios

Collaboration | Therapeutics

Biocaptiva

Seed | Medtech

BliNK Biomedical

Therapeutics

Cyted

Diagnostics

Elaitra

Seed | Data and AI | Medtech

Enedra

Pre-seed | Therapeutics

Incanthera

Therapeutics

Infinitopes

Seed | Therapeutics

iOnctura

Collaboration | Therapeutics

Mantra diagnostics

Diagnostics

Mission Therapeutics

Therapeutics

Myricx Bio

Series A | Therapeutics

Neobe Therapeutics

Seed | Therapeutics

NK:IO

Seed | Therapeutics

OligoTune

Collaboration | Pre-seed | Therapeutics

Oxomics

Diagnostics

Papivax

Therapeutics

Revitope Oncology

Therapeutics

Singula Bio

Therapeutics

Spliceor

Therapeutics

Storm Therapeutics

Therapeutics

Stratosvir

Pre-seed | Therapeutics

Stroma Biosciences

Therapeutics

Suil Vision

Seed | Data and AI

Trogenix

Seed | Therapeutics

Verinnogen

Early-stage capital | Therapeutics

Myricx Bio’s £90m Series A financing to advance ADCs to the clinic

A founder's perspective

“We are now well positioned to build on our NMTi ADC platform and advance our pipeline as we become a clinical stage company.”

-Robin Carr, CEO of Myricx

Myricx is pioneering the next generation of ADCs with a novel class of payload. Having supported the start-up and its leadership for several years, Cancer Research Horizons joined its Series A financing, one of Europe’s largest Series A funding rounds of the year, alongside leading life science investors Novo Holdings, Abingworth, Brandon Capital, Sofinnova Partners, British Patient Capital, and Eli Lilly.

Learn more